AstraZeneca COVID-19 Vaccine Woes Continue as Questions are Raised over US Trial Data

After releasing US Phase III trial data for AZD1222, more questions have been raised with AstraZeneca concerning potentially outdated information that could provide an incomplete view of efficacy.